Beijing Chunlizhengda Medical Instruments Co., Ltd. (1858) released its unaudited 2025 preliminary results, reporting total operating revenue of 1,043.77 million yuan, a 29.52% rise from the previous year. Operating profit reached 301.75 million yuan, while gross profit came in at 301.22 million yuan. Net profit attributable to owners of the parent company was 272.12 million yuan, reflecting a 117.72% increase year-on-year.

Management noted that revenue growth benefited from the continued implementation of centralized procurement in orthopedics, extensive product coverage, and steady international expansion. These factors supported both increased market share and improved profitability. During 2025, net profit after deducting non-recurring profit or loss stood at 255.11 million yuan.

By the end of 2025, total assets reached 3.66 billion yuan, up 5.58% from the beginning of the period. Owners’ equity attributable to the parent company amounted to 2.99 billion yuan, up 5.86%. Net assets per share increased to 7.78 yuan, a 5.86% rise year-on-year.